Coexpression studies involving mutant m 3 muscarinic receptors or m 3 receptor fragments Based on both theoretical and experimental data, Gouldson et al. (1998) recently proposed a model that suggests ...
Subtle changes in neurotransmission that occur during Alzheimer’s disease have been tough to track in living people. A new positron emission tomography tracer may change that. In the January 12 ...
The recent FDA approval of KarXT (Cobenfy), developed by Karuna Therapeutics (a subsidiary of Bristol Myers Squibb), marks a pivotal moment in the treatment of schizophrenia. KarXT, an oral dual M1/M4 ...
Neumora Therapeutics, Inc. has announced the initiation of a Phase 1 study for NMRA-861, a potent and selective positive allosteric modulator of the M4 muscarinic receptor, aimed at treating ...
MapLight Therapeutics, Inc. (“MapLight”) (Nasdaq: MPLT) today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to ML-007C-MA, an investigational novel M 1 ...
Please provide your email address to receive an email when new articles are posted on . Bristol Myers Squibb has completed its acquisition of Karuna Therapeutics, including Karuna’s therapeutic ...
Maplight Therapeutics Inc.’s pricing of a $258.9 million financing this week revived the debate over whether targeting the M1 as well as the M4 muscarinic receptor – as Bristol Myers Squibb Co. does ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback